SCHEMBL4811358

SCHEMBL4811358

C=CCCCCCCCCC(=O)CC=O

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.57
ABCC4 O15439 1/20 0.57
ALDH1A1 P00352 3/20 0.50
LMNA P02545 2/20 0.50
TSHR P16473 3/20 0.38
LPAR3 Q9UBY5 2/20 0.37
LPAR2 Q9HBW0 1/20 0.37
CYP3A4 P08684 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
USP2 O75604 2/20 0.37
RECQL P46063 1/20 0.37
FAAH O00519 3/20 0.35
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
DAGLA Q9Y4D2 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1301234 1.00 MAPT (0.57) MAPTABCC4ALDH1A1LMNATSHR
SCHEMBL11462977 0.87 MAPT (0.61) MAPTABCC4ALDH1A1LMNATSHR
SCHEMBL9791270 0.87 MAPT (0.61) MAPTABCC4ALDH1A1LMNATSHR
SCHEMBL5167018 0.87 MAPT (0.61) MAPTABCC4ALDH1A1LMNATSHR
SCHEMBL30197401 0.85 MAPT (0.59) MAPTABCC4ALDH1A1LMNATSHR
SCHEMBL30197206 0.85 MAPT (0.59) MAPTABCC4ALDH1A1LMNATSHR
SCHEMBL3632217 0.85 MAPT (0.59) MAPTABCC4ALDH1A1LMNATSHR
SCHEMBL19816438 0.85 TSHR (0.42) MAPTABCC4LMNATSHRCYP3A4
SCHEMBL19816442 0.85 TSHR (0.42) MAPTABCC4LMNATSHRCYP3A4
SCHEMBL5363934 0.84 MAPT (0.70) MAPTABCC4ALDH1A1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371779-B2 Synergistic compositions of N-acylhomoserine lactones and 4-quinolones THE SECRETARY OF STATE FOR DEFENSE SCIENCE AND TECHNOLOGY (GB) 2008-05-13 US claimed
US-20050014751-A1 Use of n-acyl homoserine lactones for the treatment of insulitis THE UNIVERSITY OF NOTTINGHAM (GB) 2005-01-20 US claimed
US-20040259942-A1 Modulation of stat activity SHAW PETER (GB) 2004-12-23 US claimed
EP-1404315-B1 SYNERGISTIC COMPOSITIONS OF N-ACYLHOMOSERINE LACTONES AND 4-QUINOLONES UNIV NOTTINGHAM (GB) 2004-11-03 EP claimed
US-20040198978-A1 Synergistic compositions of n-acylhomoserine lactones and 4-quinolones THE SECRETARY OF STATE FOR DEFENCE (GB) 2004-10-07 US claimed
EP-1427406-A2 MODULATION OF STAT ACTIVITY University of Nottingham (GB) 2004-06-16 EP claimed
EP-1425274-A1 USE OF N-ACYL HOMOSERINE LACTONES FOR THE TREATMENT OF INSULITIS THE UNIVERSITY OF NOTTINGHAM (GB) 2004-06-09 EP claimed
EP-1404315-A1 SYNERGISTIC COMPOSITIONS OF N-ACYLHOMOSERINE LACTONES AND 4-QUINOLONES THE UNIVERSITY OF NOTTINGHAM (GB) 2004-04-07 EP claimed
US-20030171371-A1 Immunosuppressant n-acyles homoserine lactones THE UNIVERSITY OF NOTTINGHAM (GB) 2003-09-11 US claimed
WO-2003026641-A2 MODULATION OF STAT ACTIVITY UNIVERSITY OF NOTTINGHAM (GB) 2003-04-03 WO claimed
WO-2003022828-A1 USE OF N-ACYL HOMOSERINE LACTONES FOR THE TREATMENT OF INSULITIS THE UNIVERSITY OF NOTTINGHAM (GB) 2003-03-20 WO claimed
WO-2003004017-A1 SYNERGISTIC COMPOSITIONS OF N-ACYLHOMOSERINE LACTONES AND 4-QUINOLONES THE UNIVERSITY OF NOTTINGHAM (GB) 2003-01-16 WO claimed
US-7371779-B2 Synergistic compositions of N-acylhomoserine lactones and 4-quinolones THE SECRETARY OF STATE FOR DEFENSE SCIENCE AND TECHNOLOGY (GB) 2008-05-13 US disclosed
US-20050014751-A1 Use of n-acyl homoserine lactones for the treatment of insulitis THE UNIVERSITY OF NOTTINGHAM (GB) 2005-01-20 US disclosed
US-20040259942-A1 Modulation of stat activity SHAW PETER (GB) 2004-12-23 US disclosed
EP-1404315-B1 SYNERGISTIC COMPOSITIONS OF N-ACYLHOMOSERINE LACTONES AND 4-QUINOLONES UNIV NOTTINGHAM (GB) 2004-11-03 EP disclosed
EP-1425274-A1 USE OF N-ACYL HOMOSERINE LACTONES FOR THE TREATMENT OF INSULITIS THE UNIVERSITY OF NOTTINGHAM (GB) 2004-06-09 EP disclosed
US-20030171371-A1 Immunosuppressant n-acyles homoserine lactones THE UNIVERSITY OF NOTTINGHAM (GB) 2003-09-11 US disclosed
WO-2003026641-A2 MODULATION OF STAT ACTIVITY UNIVERSITY OF NOTTINGHAM (GB) 2003-04-03 WO disclosed
WO-2003022828-A1 USE OF N-ACYL HOMOSERINE LACTONES FOR THE TREATMENT OF INSULITIS THE UNIVERSITY OF NOTTINGHAM (GB) 2003-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259942-A1 Modulation of stat activity STAT3, STAT1, STAT4 MAPT 4800/4885ABCC4 3779/4885ALDH1A1 3710/4885
US-20050014751-A1 Use of n-acyl homoserine lactones for the treatment of insulitis HPGDS, CD14, IFNG MAPT 4663/4885ABCC4 3448/4885ALDH1A1 3938/4885
US-20030171371-A1 Immunosuppressant n-acyles homoserine lactones MSR1, IL4, SRR MAPT 4833/4885ABCC4 824/4885ALDH1A1 3041/4885
US-20040198978-A1 Synergistic compositions of n-acylhomoserine lactones and 4-quinolones CBR3, CBR1, CNR1 MAPT 4873/4885ABCC4 32/4885ALDH1A1 2586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.